Related references
Note: Only part of the references are listed.Do RANKL inhibitors (denosumab) affect inflammation and immunity?
S. Ferrari-Lacraz et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Denosumab-related osteonecrosis of the jaws
A. Kyrgidis et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report
R. Rizzoli et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Bisphosphonates for post-menopausal osteoporosis: are they all the same?
R. Rizzoli
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2011)
Osteonecrosis of the jaws induced by anti-RANK ligand therapy
K. H. Taylor et al.
BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY (2010)
Adverse Effects of Bisphosphonates
Bo Abrahamsen
CALCIFIED TISSUE INTERNATIONAL (2010)
Unusual mid-shaft fractures during long-term bisphosphonate therapy
Clarita V. Odvina et al.
CLINICAL ENDOCRINOLOGY (2010)
Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer
Chris R. Cardwell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Atrial Fibrillation and Bisphosphonate Therapy
Michael Pazianas et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research
Elizabeth Shane et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Long-Term Use of Bisphosphonates in Osteoporosis
Nelson B. Watts et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison T. Stopeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Another Selective Estrogen-Receptor Modulator for Osteoporosis
Carolyn Becker
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Lasofoxifene in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab
K. A. Toulis et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database
G. Breart et al.
OSTEOPOROSIS INTERNATIONAL (2010)
The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK
C. Cooper et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity
P. Musette et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort
Jane Green et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Safety of Bisphosphonates in the Treatment of Osteoporosis
Robert R. Recker et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies
Anselm Mak et al.
BMC MUSCULOSKELETAL DISORDERS (2009)
Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation?
Philippe Lesclous et al.
BONE (2009)
Osteoporosis treatments and adverse events
Daniel H. Solomon et al.
CURRENT OPINION IN RHEUMATOLOGY (2009)
Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates A Case Series from a Swiss University Hospital
Kuntheavy Ing-Lorenzini et al.
DRUG SAFETY (2009)
Bisphosphonates and Atrial Fibrillation Systematic Review and Meta-Analysis
Yoon Kong Loke et al.
DRUG SAFETY (2009)
Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis
A. D. Anastasilakis et al.
HORMONE AND METABOLIC RESEARCH (2009)
Bisphosphonate-associated adverse events
Peter D. Papapetrou
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2009)
Current and Emerging Pharmacologic Therapies for the Management of Postmenopausal Osteoporosis
E. Michael Lewiecki
JOURNAL OF WOMENS HEALTH (2009)
Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management
Kurt A. Kennel et al.
MAYO CLINIC PROCEEDINGS (2009)
Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women
David F. Archer et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2009)
Reports of Esophageal Cancer with Oral Bisphosphonate Use
Diane K. Wysowski
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study
B. A. Lenart et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates
F. de Vries et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease
Lori Mosca et al.
STROKE (2009)
Use of alendronate and risk of incident atrial fibrillation in women
Susan R. Heckbert et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis
Rene Rizzoli et al.
BONE (2008)
Risks and benefits of bisphosphonates
R. E. Coleman
BRITISH JOURNAL OF CANCER (2008)
An overview of drug-induced acute kidney injury
Neesh Pannu et al.
CRITICAL CARE MEDICINE (2008)
Intelligent risk communication - Can it be improved?
Andrzej Czarnecki
DRUG SAFETY (2008)
Teriparatide A Review of its Use in Osteoporosis
Stephanie K. A. Blick et al.
DRUGS (2008)
Pharmacovigilance:: methods, recent developments and future perspectives
L. Harmark et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
Stuart L. Silverman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Editorial Board
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2008)
Low-energy femoral shaft fractures associated with alendronate use
Andrew S. Neviaser et al.
JOURNAL OF ORTHOPAEDIC TRAUMA (2008)
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial
John T. Grbic et al.
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION (2008)
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women
Steven Boonen et al.
KIDNEY INTERNATIONAL (2008)
Use of bisphosphonates among women and risk of atrial-fibrillation and flutter: population based case-control study
Henrik Toft Sorensen et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions
Yannick Arimone et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Alendronate and atrial fibrillation
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Strontium ranelate: New insights into its dual mode of action
Pierre J. Marie
BONE (2007)
Incidence and mortality of venous thrombosis:: a population-based study
I. A. Naess et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis - A randomized trial
Susan L. Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2007)
Osteosarcoma and teriparatide?
Kristine D. Harper et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Safety considerations with bisphosphonates for the treatment of osteoporosis
William Strampel et al.
DRUG SAFETY (2007)
Therapy Insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease
Colin R. Dunstan et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women
Elizabeth Barrett-Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
Victor G. Vogel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment
Cesar A. Migliorati et al.
LANCET ONCOLOGY (2006)
Systematic review: Bisphosphonates and osteonecrosis of the jaws
Sook-Bin Woo et al.
ANNALS OF INTERNAL MEDICINE (2006)
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
JY Reginster et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis
K Ensrud et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Intravenous ibandronate injections in postmenopausal women with osteoporosis - One-year results from the dosing intravenous administration study
Pierre D. Delmas et al.
ARTHRITIS AND RHEUMATISM (2006)
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: Results from a 6-month double-blind placebo-controlled trial
C Deal et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Safety assessment of raloxifene over eight years in a clinical trial setting
S Martino et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Skeletal effects of raloxifene after 8 years: Results from the Continuing Outcomes Relevant to Evista (CORE) study
ES Siris et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene
CS Duvernoy et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2005)
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study
JY Reginster et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: The multiple outcomes of raloxifene evaluation (MORE) randomized trial
K Yaffe et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Severely suppressed bone turnover: A potential complication of alendronate therapy
CV Odvina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Trabecular bone microarchitecture after alendronate treatment of osteoporotic women
R Recker et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Statins prevent bisphosphonate-induced γ,δ-T-cell proliferation and activation in vitro
K Thompson et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis
PJ Meunier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Safety and adverse effects associated with raloxifene: Multiple outcomes of raloxifene evaluation
D Grady et al.
OBSTETRICS AND GYNECOLOGY (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients
M Pirmohamed et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2004)
Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years
EE Jolly et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2003)
Drug-induced renal failure: Update on new medications and unique mechanisms of nephrotoxicity
MA Perazella
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2003)
Cost-equivalence of different osteoporotic fractures
LJ Melton et al.
OSTEOPOROSIS INTERNATIONAL (2003)
Patients' understanding of risk associated with medication use - Impact of European Commission guidelines and other risk scales
DC Berry et al.
DRUG SAFETY (2003)
Protective effects of estrogen and selective estrogen receptor modulators in the brain
KM Dhandapani et al.
BIOLOGY OF REPRODUCTION (2002)
Oral bisphosphonates and upper gastrointestinal tract problems: What is the evidence?
B Cryer et al.
MAYO CLINIC PROCEEDINGS (2002)
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2002)
Provision of information about drug side-effects to patients
DC Berry et al.
LANCET (2002)
Upper gastrointestinal tract safety of risedronate: A pooled analysis of 9 clinical trials
H Taggart et al.
MAYO CLINIC PROCEEDINGS (2002)
Design and methods of the raloxifene use for the heart (RUTH) study
L Mosca et al.
AMERICAN JOURNAL OF CARDIOLOGY (2001)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Adverse drug reactions: definitions, diagnosis, and management
IR Edwards et al.
LANCET (2000)
Raloxifene - A review of its use in postmenopausal osteoporosis
D Clemett et al.
DRUGS (2000)
Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials
FJ Cohen et al.
MATURITAS (2000)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
